Suggested remit: To appraise the clinical and cost effectiveness of lifileucel within its marketing authorisation for previously treated unresectable or metastatic melanoma.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Process:
- STA Standard
- ID number:
- 3863
Provisional Schedule
- Committee meeting:
- 04 November 2025
Project Team
- Project lead
- Jenniffer Upton
Email enquiries
If you have any queries please email [email protected]
Stakeholders
- Companies sponsors
- Iovance Biotherapeutics
- Others
- Department of Health and Social Care
- NHS England
- Welsh Government
- Professional groups
- Association of Cancer Physicians
- Cancer Research UK
- Melanoma Focus
- Royal College of Physicians
- Royal College of Radiologists (RCR)
- Associated public health groups
- Public Health Wales
- UK Health Security Agency
- Comparator companies
- Bristol-Myers Squibb Pharmaceuticals Ltd (BMS)
- Merck Sharp & Dohme
- General commentators
- All Wales Therapeutics and Toxicology Centre
- British National Formulary (BNF)
- Department of Health - Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- NHS Wales Joint Commissioning Committee
- Scottish Medicines Consortium
- Welsh Government
- Relevant research groups
- Institute of Cancer Research
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 08 January 2025 | Invitation to participate |
| 27 September 2024 | Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in early January 2025. These timings are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust submission. |
| 24 July 2024 - 21 August 2024 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 3863 |
| 24 July 2024 | In progress. Scoping commenced. |
| 01 May 2024 | Please note that following on from advice received from the company this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during late September 2024 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately late November 2024. |
| 16 January 2024 | Please note that following on from advice received from the company this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during late August 2024 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately late October 2024. |
| 03 April 2023 | Following the changes to remove technical engagement as standard from appraisal timelines, the timelines for the appraisal of Lifileucel for previously treated unresectable or metastatic melanoma have been revised. It is anticipated that the appraisal will begin in late-May 2024 when we will write to you about how you can get involved. |
| 02 December 2022 | Please note that following an update received from the company this appraisal is still to be rescheduled to align with latest regulatory expectations. Further information regarding the timelines for this appraisal will be available during second half 2023. |
| 30 March 2021 | Please note that following on from advice received from the company this appraisal will be rescheduled to align with latest regulatory expectations. Further information regarding the timelines for this appraisal will be available in due course. |
For further information on our processes and methods, please see our CHTE processes and methods manual